Heron Therapeutics, Inc. (HRTX) Earnings Call Transcript & Summary
May 7, 2024
Earnings Call Speaker Segments
Melissa Jarel
executiveThanks, operator, and hello everyone. We're glad you could join this Heron Therapeutics call, where we'll be reviewing how the company performed financially during the quarter that ended March 31, 2024. Here with me from Heron are our Chief Executive Officer, Craig Collard; Ira Duarte, who serves as Executive Vice President and Chief Financial Officer; and Bill Forbes, Executive Vice President and Chief Development Officer. Those of you listening by telephone can also access a webcast, which will remain available after we finish today, reachable via the Investor Relations section of our website. One brief note before we proceed: throughout this call, the company will be issuing forward-looking statements. Before we go further, keep in mind that anything we say today that isn't strictly a fact about what's already happened should be treated as forward-looking. That includes anything about where the company expects to go, what we're planning, what we believe, and how we think we'll perform down the road — all of it falls under the forward-looking label for purposes of the safe harbor protection created by the Private Securities Litigation Reform Act of 1995. Statements like these are based on our best judgment and analysis at the time of this call, and they come with a lot of significant risks and uncertainties that could cause what actually happens to differ materially from what those forward-looking statements describe. Details about the dangers and unknowns connected to predictive remarks shared during this conference call and webcast can be found in the safe harbor statement included in today's press release, as well as in Heron's public shareholders' filings with the SEC. Unless the law demands it, Heron takes on no duty to revise these forward-looking statements so they mirror upcoming occurrences or real results, and it has no plans to do so. Having said that, I would now like to hand the call over to Craig Collard, Chief Executive Officer of Heron.
Craig Collard
executiveThanks, Melissa. Good morning to all of you, and thank you for joining the Heron Therapeutics' First Quarter 2024 Earnings Call. We're happy today to bring you up to date on what we've accomplished most recently in Q1, covering our financial results, the advancement of our development programs, how CrossLink is progressing, and a broader corporate update. We kicked off the quarter with enormous momentum. To begin, the CrossLink agreement was signed by us on January 7, and then, not long afterward, on January 23, we obtained official approval for the expanded indication of ZYNRELEF, which extends our label into spine, shoulder and other soft tissue surgical procedures. Following these 2 events, we held a National Sales Meeting at which we trained every one of our sales staff on the new indications; we also put together an internal group to lead the training process for the CrossLink team. We've kept enhancing our financial efficiency through lower spend and better margins. Our belief is that, by staying on this path, we will reach profitability, as predicted, by Q4 of 2024. Before turning to product performance, I wanted to present this slide to point out what was accomplished this quarter compared with merely 12 months ago. As you can see, in Q1 of 2023, net revenues came to $29.6 million, COGS was $16.8 million, and the overall loss was just over $33 million. During the same period in 2024, net revenues reached $34.6 million, COGS was $8.4 million, and the loss came to $4.8 million — a positive swing of $28.2 million in only 12 months, together with gross margin improvement from 43% to 76%. What we take from this is that we're headed in the right direction and the business is well-positioned for what lies ahead. Now, turning to product performance, the Oncology franchise keeps exceeding our expectations, with CINVANTI net revenues of $25.6 million for the quarter and SUSTOL net revenues of $3.6 million for the quarter; we continue to hold our current market share in a highly competitive environment within the oncology franchise, and we expect these products to keep delivering a safe consistency through 2024. Total Acute Care net revenues for the quarter were $5.5 million, an increase of 45% from $3.8 million in the first quarter of 2023. ZYNRELEF net revenues for the quarter came to $5 million, marking the second consecutive quarter with revenues of $5 million or more. APONVIE net revenues for the quarter kept rising quarter-on-quarter and year-on-year, reaching $500,000 for the quarter ended March 31, 2024. Although we're happy with the direction we're moving in, we knew Q1 would be comparatively flat given seasonality and all the other activities taking place during the quarter, such as label expansion training and the launch of CrossLink. I'll address ZYNRELEF's performance specifically shortly, when I provide an update on CrossLink, but I wanted to note that we're seeing enormous uptake with APONVIE. The way we're telling the sales story is genuinely starting to land with a lot of institutions across the nation, and ultimately that's going to flow through and affect how net revenue grows. During the third quarter of 2023, the new leadership group here came to understand that when it came to APONVIE, the pitch had to center on the PONV problem itself rather than simply attempting to switch over oral premising and the financial consequences that can arise in the perioperative setting. So we put our reps through retraining, sharpened the way we present the product, and adjusted the incentive compensation structure so it aligned with that message. Since we rolled this out in October 2023, we've notched more than 70 P&T wins, and another 35 came in this quarter, which the slide makes clear. After P&T gives the green light, some delay occurs before the sales bolus really starts building. Still, as these accounts join the fold, sales should keep climbing, since in most accounts APONVIE tends to bill system-wide. The momentum behind APONVIE has us quite encouraged, and it ought to keep getting better. Bringing additional CrossLink reps aboard will mean our Heron people gain more hours to actually go sell APONVIE and ZYNRELEF, instead of standing in the OR while cases are managed for ZYNRELEF preparation. Turning now to the CrossLink update: training for that team began with the executive group in late February and with the reps in early March; at this point 216 CrossLink reps <<inaudible>> joint, trauma and spine are fully trained and out selling ZYNRELEF in the field. The payoff from the CrossLink partnership isn't visible yet in Q1, but we think the way the partnership and the training were timed and staged, with training still under way, will deliver plenty of dividends as additional field reps come online. Our intention is to keep widening our reach nationwide, with more than 650 reps fully trained and integrated ahead of the VAN launch in Q4 of this year. On our end, the ties the CrossLink team holds within the orthopedic surgical community have truly impressed us, and we recognize that over time this will significantly affect ZYNRELEF revenues. In merely 1 month of their joint team being trained and promoting ZYNRELEF, we already saw more than 20 new orthopedic surgeons try our product during that first month; that's only in North Carolina, South Carolina, and Georgia, the inaugural region of our partnership with CrossLink. Unit sales growth across these 3 states has risen 12-fold compared with the rest of the country. We logged roughly 60 introductions and touchpoints with new ortho users during April by itself, and we expect 40 new users to join within the coming 30 days. We're honestly at the very beginning here, assembling the vehicle even as we're on the road, yet what CrossLink is going to deliver is quite evident, and it will keep unfolding as additional reps complete their training and become part of the partnership. At this point I'll hand things over to Bill Forbes, who serves as our Chief Development Officer. The floor is yours, Bill.
Bill Forbes
executiveThanks, Craig. On our previous quarterly earnings call, I went over the R&D work we're doing, which centers on making ZYNRELEF easier to access. For investors who are newer to our story, I'll go through some of that once more, and I'll also give an update on what we're working on now along with what we expect to deliver in the near term. After the ZYNRELEF label expansion, R&D remains focused on efforts to change the device portion of this combination product. The first change concerns the Vial Access Needle, or VAN. The VAN is built to make preparation more efficient, and it does so in 2 ways. First, pulling ZYNRELEF out of the vial using the VAN takes roughly 3 to 4x less time than the Basic Vial Spike, or BVS, that is on the market today. Second, by enclosing the ZYNRELEF vial within the VAN's sterile shroud, the VAN will enable a more secure presentation of the product into the sterile field in the surgical room. We think operating room staff will respond very favorably to both the shorter withdrawal time and the sterile shroud. Right now, all development and testing work on the VAN is finished, and we are wrapping up the submission to the FDA. We expect the VAN to be approved in Q4 of this year. The prefilled syringe, or PFS, is the ultimate answer for speed and ease of use with ZYNRELEF. We expect the PFS to be approved in Q4 of 2026; with this product presentation, the whole tray is sterilized and ready to use right away. There will be no vial OF ZYNRELEF and no BVS or VAN, just the syringe itsef. A new container closure system and the sterilization process itself are the challenges for this program. Once it becomes available, every barrier to preparation will be gone. With that, I'll hand things over to Ira Duarte. Ira?
Ira Duarte
executiveThanks, Bill. Craig already went over how our products did and what happened with OpEx, so I'll just add a few more things about what we saw in Q1 2024. Product gross profit came to $26.2 million in the first quarter, which works out to 76%, up from 43% in Q1 2023. The gains we got from scaling up production, from validation work, and from qualifying raw materials, all of which wrapped up late in 2022, showed up more completely in 2024 than they did during the same stretch of 2023. SG&A for the 3 months ended March 31, 2024 came in at $26.4 million, versus $37 million for the same period in 2023. That drop mostly came from lower personnel and related costs tied to the reduction force we put in place in June 2022 and June 2023. R&D came to $4.6 million for the 3 months ended March 31, 2024, against $8.8 million in the comparable 2023 period. That decline was mainly from lower personnel and related costs tied to the reduction in force from both June 2022 and June 2023. As we note in the 10-Q, the condensed, consolidated statements of operations and comprehensive loss as of March 31, 2024 show certain expenses reclassified out of research and development and into general and administrative expenses, so they line up with the function of the expenses incurred. Total operating expenses don't change as a result. Net loss was $3.2 million in Q1 2024 and $32.7 million in the comparable 2023 period. We're reaffirming the guidance we gave before: revenue of $138 million to $158 million for 2024, and gross margin improving to between 68% and 70%. Operating spend, leaving out stock compensation along with depreciation and amortization, should land between $108 million and $116 million, and EBITDA, leaving out stock comps, will land somewhere between a loss of $22 million and income of $3 million. Let me repeat that we expect <<inaudible>> to positive EBITDA in Q4 2024. Given that, along with our strong balance sheet and our current operational plan, we don't expect we'll need to raise additional capital. At this point we'd like to open the call for any questions.
Serge Belanger
analyst<<inaudible>> Craig, roughly 4 months have passed since ZYNRELEF received that broad label expansion. You mentioned a few of the newly added indications. I believe spine, shoulder, and soft tissue procedures were among them. When do you expect the extra uptake from those new indications to show up? And second, I saw that you had a solid first quarter. I'm wondering whether that represents a sort of new baseline for the product moving forward.
Craig Collard
executiveMy apologies. Could you say the first part again? A portion of the beginning of your question got cut off.
Serge Belanger
analystYeah. So ZYNRELEF's broad label expansion happened roughly 4 months back. A bunch of new indications have come along. Spine, shoulder, and soft tissue were the ones you brought up. I'm wondering where this product has picked up traction within those newly added indications since the label got expanded.
Craig Collard
executiveSo honestly, what's kind of funny is that on approval day 1, I personally got to be present in a spine procedure. There was a physician in North Carolina who utilized it, and I was able to observe. But I believe what you're seeing unfold is that we've definitely had plenty of spine surgeons, orthopedic folks and others who have given the product a try, perhaps for shoulder or spine. Yet I think, once more, adoption is going to be — while folks will use it, I think there's still going to be a degree of experimentation regarding the way they administer it, becoming familiar with the product and sort of moving through that entire kind of process we experience with a product such as this. It's somewhat different. So I think what we've observed thus far has been positive; among the cases we've handled, a few of — the case I attended on that particular day, everything went smoothly. Kevin Warner is also present. I'm not sure, Kevin, whether you might have any thoughts too that you could perhaps contribute on that?
Kevin Warner
executiveAbsolutely, and I appreciate that question, Serge. When it comes to the broader label, there are a few implications. To start with, formulary access — frequently, whenever these organizations evaluate a product, they prefer to be able to adopt it and have it covered across every procedure they perform, rather than dealing with a piecemeal situation involving several branded options sitting on their shelves. So securing that wider label represented a substantial step forward for us in terms of formulary access. All of these things require time, correct? The review cycle alone runs 2 to 3 months, plus building it into the electronic medical record. So the rollout and the impact of that broader label will really show up in Q3 and Q4 as we broaden our education efforts around it and what it delivers. Regarding procedures, there are certainly some important target ones. One strong example that resonates with most people is the soft tissue area involving C-section. Clearly, with a new mother, we don't want to subject her to opioids, and that procedure is quite painful, so we can support her recovery, help her leave the hospital without opioid exposure and without exposing that infant to opioids either. That said, the other orthopedic procedures — spine and shoulder — remain the main focus, and we are achieving outstanding outcomes in those.
Craig Collard
executiveAbsolutely, Serge. As for the latter portion of what you asked about CINVANTI — look, CINVANTI and SUSTOL have left us quite delighted. My view is that each turned in a strong quarter. Once more, our unit volume has risen, and we're keeping price at a fairly steady level; so quarter to quarter, there is some fluctuation, yet the market continues to expand, and our share is holding; and so, once again, CINVANTI has pleased us greatly, and the clinical benefit it delivers is certainly assisting us in keeping share and sustaining price.
Serge Belanger
analystGood advancement.
Carl Byrnes
analystWell done on the quarter and the headway. Given the demand patterns clearly taking place everywhere and the expense cuts plus improvement in gross profit margin, do you figure it's feasible you could reach profitability before the fourth quarter you're guiding toward?
Craig Collard
executiveAppreciate the question. I figured someone would bring that up. Honestly, we're quite happy with how things are progressing. And once more, we're a touch below. Clearly, the expense range we provided was $108 million to $116 million; and if you simply take that times 4, clearly, we're at the bottom end of it, and we hope that keeps up. I believe our possible rationale for not raising guidance or tightening guidance right now is truly because of continuing litigations we have. And once more, we're — though we sense we've got the business in hand and we have this managed, there remain items occurring on the development side and in the legal area that might shift somewhat. So we're attempting to stay a bit careful here. I suppose perhaps cautious is the right word. But once more, we're quite happy with how things are progressing, and we — with how expenses turned out this quarter. On margins, once more, one factor that's aided us, we have renegotiated several items with our manufacturers and that has helped hold certainly COGS down. Yet we also this quarter mostly just used APONVIE with CINVANTI. And so we have a secondary manufacturer too that we have not utilized this quarter. And so that has assisted margins somewhat, bringing us up to roughly the 76% range. I still believe, across the year, we're going to be at the bottom end of the 70% range; but once more, we're going to try to handle that as well as we can. But we're incredibly happy with where we are, and we're hoping that, once more, we finish up at the bottom end of that expense range. And so if that comes to pass, clearly, there's a chance we could reach profitability sooner; but right now, we're still dedicated to Q4.
Tim Chiang
analystCraig, might you expand a bit further on those CrossLink representatives you folks have put through training? My recollection is you mentioned a figure above 200. You also brought up 3 particular states where you've already gained a foothold. Which additional states are on the agenda for this summer? And by the time fall arrives, what number of CrossLink reps do you expect to have completely trained?
Craig Collard
executiveTim, I appreciate that. Once more, our feelings about CrossLink have been very positive. I know I called it amazing in my remarks, but the connections these individuals carry are simply not quite the same as what a pharma company like ours possesses. Bear in mind that frequently — CrossLink has existed for 4 years now; and many of the reps carry 10, 15, 20 years of experience alongside these physicians, seeing them daily. That makes for a relationship of a different kind. What this does is let us stand before these people; it gives us extra time to walk through certain matters involving ZYNRELEF and similar topics. As we've said, it opens up bandwidth for our own reps and so on. On the training side, though, we've once more been progressing at a good clip. I'd like to hand things to David Barozzino. He has been right in the middle of it and has attended those training — the meetings, and he can offer you further detail on precisely what's happening and our next destination.
David Barozzino
executiveAbsolutely. Thanks, Craig. And Tim, I appreciate the question. When it comes to CrossLink, sure, we began in those legacy states where CrossLink already operates — North Carolina, South Carolina, and Georgia. Yet something that keeps happening and keeps shifting is that every week, we're running 2 to 3 live training sessions nationwide. By the close of 2024, the aim is to be present in every state. I can share that we've already grown into places such as Michigan, St. Louis, and Kansas, and it keeps developing week by week. Still, before the year ends, we certainly expect to have coverage across all 50 states.
Tim Chiang
analystAlright, that's excellent. Perhaps only a single item then. From what I remember, Florida happens to be quite a large state when it comes to procedures. So, do you folks intend to enter that market in the near future?
Craig Collard
executiveAbsolutely, 100%. We — that's certainly a key priority for us. You could group places such as New York, Florida, Texas, California together as 4 major states. Plus, we're currently in ongoing talks with a few distributors located down there too.
Tim Chiang
analystAll right. Great. That's really useful. Thank you.
Kelly Shi
analystThis is Clare sitting in for Kelly. Congratulations on the quarter. So, regarding ZYNRELEF, would you mind discussing how you qualify under the NOPAIN Act, given your pass-through status, and what will happen to coverage once it kicks in during 2025? Also, could you share any details on the most recent talks about whether the NOPAIN Act might extend past 2027?
Kevin Warner
executiveYeah, Kevin Warner here again. I appreciate the question. The NOPAIN Act takes effect in Q1 of 2025; it will deliver reimbursement separate from the surgical bundle for our HOPD patients, our hospital outpatient procedure department, and our ASCs, for these non-opioids that are proven to cut opioid consumption. So at present, ZYNRELEF holds pass-through, as you mentioned, and that runs out in Q1 of 2025. So the NOPAIN Act begins in Q1. We've had discussions already with CMS, very productive ones, and we laid out every criterion needed to qualify under the NOPAIN Act, and ZYNRELEF meets all of them but one, and that one is the fact that we hold pass-through status. That's the reason we had this open dialogue, to ensure we don't drop off during that interim period. And we're confident they will pick it up and pass it through immediately. There won't be any hitch in that pass-through status, so our institutions continue to have access and reimbursement for ZYNRELEF. On the question of extending the duration, the NOPAIN Act was initially designed as a 5-year act. Unfortunately, getting it through Congress took some time, so it came a little later than desired, but as of right now, through the end of '27, as expected. We certainly have plenty of encouragement and support from our community, and obviously, the opioid epidemic, the concerns around that. We expect them to keep extending and providing payments for these non-opioids for our country and for our patients.
Analyst
analystThat's really useful.
Craig Collard
executiveOnce more, I'd like to express my gratitude to all of you for tuning in today, and we can't wait to talk with all of you again in the next quarter. Thanks.
Operator
operatorThat wraps up our session for today, everyone. We appreciate each of you for being here. You're free to leave the line now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Heron Therapeutics, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to Heron Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Heron Therapeutics, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.